Moderna’s second-quarter sales fell less sharply than Wall Street expected as it works to expand its offerings amid weakening demand for its Covid-19 vaccine.

Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which came in above the company’s expectations thanks to a “stronger-than-expected U.S. spring booster season,” CFO Jamey Mock said on an analyst call Friday.